Clinical Report: Integration of Multi-Omics Approaches Reveals APOE as a Key Metabolic Modulator in Macrophage-Fibroblast Interaction in Idiopathic Pulmonary Fibrosis

Overview

This study identifies APOE as a crucial metabolic modulator in the interaction between macrophages and fibroblasts in idiopathic pulmonary fibrosis (IPF).

Background

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized by excessive extracellular matrix deposition and irreversible remodeling. The interplay between immune dysregulation and metabolic anomalies in IPF is similar to that observed in neurodegenerative diseases, particularly Alzheimer's disease (AD). Understanding the genetic and metabolic connections between these conditions may reveal new therapeutic targets.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

• APOE is identified as a key hub gene enriched in lung macrophages, influencing macrophage-fibroblast interactions.
• Mendelian randomization analysis indicates that genetic liability to Alzheimer's disease is associated with a decreased risk of developing IPF.
• Pseudotime modeling reveals a pathogenic bifurcation in IPF, with macrophages showing oxidative phosphorylation defects and increased secretion of SPP1.
• The loss of APOE function in macrophages leads to hyperactivation of complement and antigen-presentation pathways.
• APOE ablation in macrophages significantly enhances myofibroblast differentiation in co-culture assays with fibroblasts.

Clinical Implications

Understanding the role of macrophages in fibroblast activation could inform future treatment strategies.

Conclusion

APOE serves as a critical metabolic barrier in the lung, influencing macrophage polarization and fibroblast activation in IPF.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Identification of potential therapeutic targets for idiopathic pulmonary fibrosis: an integrated multiomics analysis
2. Frontiers in Immunology, 2026 -- Microbiome-innate immune crosstalk in acute exacerbation of idiopathic pulmonary fibrosis: an amplification framework
3. Frontiers in Immunology, 2026 -- NAMPT orchestrates fibroblast cuproptosis and immune crosstalk during IPF progression
4. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline - PMC
5. Frontiers in Immunology — Natural therapeutics and traditional formulas targeting macrophage polarization in the fibrotic niche of idiopathic pulmonary fibrosis
6. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline - PMC
7. Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis | New England Journal of Medicine
8. Annual Review of Physiology